IMMUNEONCO BIOPHARMACEUTICALS (SHAN revenue for the last year amounted to 424.65 k HKD, the most of which — 405.53 k HKD — came from its highest performing source at the moment, Cell Strain and Other Products, the year earlier bringing 580.28 k HKD. The greatest contribution to the revenue figure was made by China — last year it brought IMMUNEONCO BIOPHARMACEUTICALS (SHAN 426.53 k HKD, and the year before that — 625.63 k HKD.